𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Human malignant glioma cell lines are sensitive to low radiation doses

✍ Scribed by Patrick D. Beauchesne; Suzanne Bertrand; Robert Branche; Steven P. Linke; Roland Revel; Jean-François Dore; Rémy M. Pedeux


Publisher
John Wiley and Sons
Year
2003
Tongue
French
Weight
182 KB
Volume
105
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Malignant gliomas display aggressive local behavior and are not cured by existing therapy. Some cell lines that are considered radioresistant respond to low radiation doses (<1 Gy) with increased cell killing (low‐dose hypersensitivity). In our study, 4 of 5 human glioma cell lines exhibited significant X‐ray sensitivity at doses below 1 Gy. The surviving fractions (SFs) obtained at 0.7 and/or 0.8 Gy were comparable to those at 1.5 Gy. Low‐dose hypersensitivity was evident when irradiation was combined with etoposide treatment. Repeated irradiation with low doses was markedly more effective than irradiation with single, biologically equivalent doses in decreasing SFs, inhibiting xenograft tumor growth in mice. All experiments were conducted with an accelerator used in clinics, establishing that low‐dose hypersensitivity was present following megavoltage X‐irradiation. Thus, repeated low‐dose irradiation (ultrafractionation) could greatly improve the effectiveness of radiotherapy of gliomas and could allow safe treatment of patients with cumulative doses greater than 60 Gy. © 2003 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


IUdR polymers for combined continuous lo
✍ Xuan Yuan; Larry E. Dillehay; Jerry R. Williams; Jeffery A. Williams 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 255 KB

## Abstract Local polymeric delivery enhances IUdR radiosensitization of human malignant gliomas (MG). The combined low‐dose rate (LDR) (0.03 Gy/h) and fractionated high‐dose rate (HDR) treatments result in cures of experimental MGs. To enhance efficacy, we combined polymeric IUdR delivery, LDR, an

Farnesyltransferase inhibitor, R115777,
✍ Caroline Delmas; Christophe Heliez; Elizabeth Cohen-Jonathan; Dave End; Jacques 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 425 KB

## Abstract We investigated for the first time the ability of farnesyltransferase inhibitors (FTI) to radiosensitize human glioma. For this, human glioma cell lines were treated with the specific FTI, R115777, 48 hr prior to a 2Gy irradiation. The treatment with R115777 decreased by 45% the SF2 val

Chromosomal imbalances associated with r
✍ Ruthild G. Weber; Johannes Rieger; Ulrike Naumann; Peter Lichter; Michael Weller 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 124 KB 👁 2 views

The median survival for human malignant glioma patients treated with neurosurgery and postoperative radiotherapy does not exceed one year. Only a minority of patients benefit from adjuvant chemotherapy. It was the aim of our study to determine which genomic alterations in malignant gliomas modulate

Human breast cancer cell lines resistant
✍ Anne E. Lykkesfeldt; Søren S. Larsen; Per Briand 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 760 KB

## Abstract The pure steroidal anti‐estrogens ICI 164,384 and ICI 182,780 are very potent growth inhibitors of the estrogen receptor‐positive human breast cancer cell line MCF‐7. However, long‐term treatment of MCF‐7 cells with 10^−7^ M concentrations of these compounds results in selection of prol

Truncated midkine correlates with sensit
✍ Natsuyo Akuzawa; Shigenori Nobata; Takao Shinozawa 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB

## Abstract Midkine (MK) is a heparin binding growth factor having functions of neurite‐outgrowth, mitogenesis and tissue repair. This molecule is involved in tumor growth and metastasis. The MK molecule consists of five exons, but there is a truncated isoform, lacking exon 3. We established SW13 c

Yuan X, Dillehay LE, Williams JR, Shastr
✍ X Yuan; LE Dillehay; JR Williams; VR Shastri; JA Williams 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 28 KB

## Abstract The original article to which this Erratum refers was published in International Journal of Cancer (Radiation Oncology Investigations) 2001; 96(2) 118–125